The Role of Adipokines as Circulating Biomarkers in Critical Illness and Sepsis

Sepsis represents a major global health burden. Early diagnosis of sepsis as well as guiding early therapeutic decisions in septic patients still represent major clinical challenges. In this context, a whole plethora of different clinical and serum-based markers have been tested regarding their pote...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2019-09, Vol.20 (19), p.4820
Main Authors: Loosen, Sven H, Koch, Alexander, Tacke, Frank, Roderburg, Christoph, Luedde, Tom
Format: Article
Language:English
Subjects:
Adipokines - blood
Animal models
Animals
Biomarkers
Cardiovascular disease
Case-Control Studies
Critical Illness
Early Diagnosis
Humans
Illnesses
Immune response
Infectious diseases
Inflammation
Metabolism
Obesity
Pathophysiology
Physiology
Prognosis
Proteins
Public health
Review
Sepsis
Sepsis - blood
Sepsis - diagnosis
Streptococcus infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sepsis represents a major global health burden. Early diagnosis of sepsis as well as guiding early therapeutic decisions in septic patients still represent major clinical challenges. In this context, a whole plethora of different clinical and serum-based markers have been tested regarding their potential for early detection of sepsis and their ability to stratify patients according to their probability to survive critical illness and sepsis. Adipokines represent a fast-growing class of proteins that have gained an increasing interest with respect to their potential to modulate immune responses in inflammatory and infectious diseases. We review current knowledge on the role of different adipokines in diagnostic work-up and risk stratification of sepsis as well as critical illness. We discuss recent data from animal models as well as from clinical studies and finally highlight the limitations of these analyses that currently prevent the use of adipokines as biomarkers in daily practice.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms20194820